Schedule 13D Filing by Braeden Lichti and Northstrive Fund II LP for Bluejay Diagnostics, Inc.

Braeden Lichti and Northstrive Fund II LP (Reporting Persons) have filed a Schedule 13D, amending a previous Schedule 13G, concerning their beneficial ownership of Bluejay Diagnostics, Inc. common stock. As of March 10, 2026, Mr. Lichti beneficially owned 35,500 shares (3.65% ownership) and Northstrive Fund beneficially owned 11,000 shares (1.13% ownership). The filing was prompted by a letter sent by Northstrive Fund to Bluejay's Board of Directors recommending the review of a potential biotechnology acquisition opportunity to enhance the company's clinical pipeline and create shareholder value. The Reporting Persons have the intent to potentially change or influence the control of the Issuer. They will continue to review their investment and may take actions such as liquidating or accumulating more shares. The letter also suggests an acquisition of a Phase-1-ready therapeutic asset targeting refractory chronic cough (RCC), a market estimated to exceed $10 billion annually. The proposed asset has a differentiated mechanism of action and potential for expansion into other indications. The Reporting Persons have identified a parallel financing opportunity of approximately $5,000,000 through a public company financing structure.